MR Imaging in Multiple Sclerosis: Review and Recommendations for Current Practice

被引：70

作者：

Loevblad, K.-O. ^{[1
]}

Anzalone, N. ^{[2
]}

Doerfler, A. ^{[4
]}

Essig, M. ^{[5
]}

Hurwitz, B. ^{[6
]}

Kappos, L. ^{[7
]}

Lee, S. -K. ^{[8
]}

Filippi, M. ^{[3
]}

机构：

[1] Univ Hosp Geneva, Diagnost Neuroradiol Unit, Dept Radiol, CH-1211 Geneva 14, Switzerland

[2] Ist Sci San Raffaele, Dept Neuroradiol, I-20132 Milan, Italy

[3] Ist Sci San Raffaele, Neuroimaging Res Unit, Dept Neurol, I-20132 Milan, Italy

[4] Univ Erlangen Nurnberg, Dept Neuroradiol, Erlangen, Germany

[5] German Canc Res Ctr, Dept Radiol, D-6900 Heidelberg, Germany

[6] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

[7] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland

[8] Yonsei Univ, Coll Med, Dept Radiol, Seoul, South Korea

来源：

AMERICAN JOURNAL OF NEURORADIOLOGY | 2010年 / 31卷 / 06期

关键词：

NEPHROGENIC SYSTEMIC FIBROSIS; CLINICALLY ISOLATED SYNDROMES; 1ST DEMYELINATING EVENT; CONTRAST AGENTS; GADOBENATE-DIMEGLUMINE; DIAGNOSTIC-CRITERIA; GLATIRAMER ACETATE; ENHANCING LESIONS; DOSE GADOTERIDOL; NATURAL-HISTORY;

D O I：

10.3174/ajnr.A1906

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

MR imaging is widely used for the diagnosis and monitoring of patients with MS. Applications and protocols for MR imaging continue to evolve, prompting a need for continual reassessments of the optimal use of this technique in clinical practice. This article provides updated recommendations on the use of MR imaging in MS, based on a review of the trial evidence and personal experiences shared at a recent expert meeting of radiologists and neurologists.

引用

页码：983 / 989

页数：7

共 58 条

[11] MRI as an outcome in multiple sclerosis clinical trials
Daumer, M.
Neuhaus, A.
Morrissey, S.
Hintzen, R.
Ebers, G. C.
[J]. NEUROLOGY, 2009, 72 (08) : 705 - 711
[12] Enhancing lesions of the brain: Intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators
Essig, Marco
Tartaro, Armando
Tartaglione, Tomasso
Pirovano, Gianpaolo
Kirchin, Miles A.
Spinazzi, Alberto
[J]. ACADEMIC RADIOLOGY, 2006, 13 (06) : 744 - 751
[13] A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis -: Implications for phase II clinical trials
Filippi, M
Rovaris, M
Capra, R
Gasperini, C
Yousry, TA
Sormani, MP
Prandini, F
Horsfield, MA
Martinelli, V
Bastianello, S
Kühne, I
Pozzilli, C
Comi, G
[J]. BRAIN, 1998, 121 : 2011 - 2020
[14] Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes"
Filippi, M
Rovaris, M
Rocca, MA
Sormani, MP
Wolinsky, JS
Comi, G
[J]. NEUROLOGY, 2001, 57 (04) : 731 - 733
[15] Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis
Fisniku, L. K.
Brex, P. A.
Altmann, D. R.
Miszkiel, K. A.
Benton, C. E.
Lanyon, R.
Thompson, A. J.
Miller, D. H.
[J]. BRAIN, 2008, 131 : 808 - 817
[16] Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C
Frenzel, Thomas
Lengsfeld, Philipp
Schirmer, Heiko
Huetter, Joachim
Weinmann, Hanns-Joachim
[J]. INVESTIGATIVE RADIOLOGY, 2008, 43 (12) : 817 - 828
[17] Fujihara Kazuo, 2005, Int MS J, V12, P34
[18] Ge Y, 2006, AM J NEURORADIOL, V27, P1165
[19] Ge YL, 2005, AM J NEURORADIOL, V26, P2316
[20] Neuroinflammation in multiple sclerosis: Evidence for autoimmune dysregulation, not simple autoimmune reaction
Grigoriadis, N
Grigoriadis, S
Polyzoidou, E
Milonas, I
Karussis, D
[J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2006, 108 (03) : 241 - 244

← 1 2 3 4 5 6 →